# A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity

> **NCT06974851** · PHASE3 · RECRUITING · sponsor: **Fujian Shengdi Pharmaceutical Co., Ltd.** · enrollment: 140 (estimated)

## Conditions studied

- Bstructive Sleep Apnea (OSA) and Obesity

## Interventions

- **DRUG:** HRS9531
- **DRUG:** HRS9531placebo

## Key facts

- **NCT ID:** NCT06974851
- **Lead sponsor:** Fujian Shengdi Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-25
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06974851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06974851, "A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06974851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*